Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
Year: 2021
Type: article
Study design: Clinical Trial
Abstract: Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12-175 [NCT01328626]; M13-365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax monotherapy could receive added rituximab. Ten patients were evaluated (M12-175, n = 8; M13-365, n = 2), and five (50%) responded again upon addition of rituximab, including three complete and two partial responses. Responses were ongoing after 5-10 months of follow-up. Addition of rituximab was well tolerated. These findings indicate potential clinical benefit with rituximab added to venetoclax post-progression in some patients with R/R CLL.
Source: eJHaem
DOI: 10.1002/jha2.177
Institutions: The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, Dana-Farber Cancer Institute, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Roche (United Kingdom), AbbVie (United States)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,250
OpenAlex ID: W3133932532